Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Alexander Edward Dela Cruz Drilon, Zishuo I. Hu, Gillianne Geet Yi Lai et al. · Nature Reviews Clinical Oncology · 2017
Cited by 406 works. doi:10.1038/nrclinonc.2017.175
Authors
References
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- Comprehensive molecular profiling of lung adenocarcinoma
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations